PnuBioVax™: next-generation vaccine for a personalised and effective immune response against Streptococcus pneumoniae.

Project Information

PnuBioVax

Grant agreement ID: 866570

DOI

10.3030/866570

Project closed

EC signature date 11 May 2019

Start date 1 May 2019

End date 30 September 2019

Funded under

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Total cost

€ 71 429,00

EU contribution

€ 50 000,00

Coordinated by

IMMUNOBIOLOGY LIMITED
United Kingdom

Periodic Reporting for period 1 - PnuBioVax (PnuBioVax™: next-generation vaccine for a personalised and effective immune response against Streptococcus pneumoniae.)

Reporting period: 2019-05-01 to 2019-09-30

Summary of the context and overall objectives of the project

The prevention of pneumococcal diseases is a global challenge that has been partially addressed through vaccination. Some of the societal issues associated with pneumococcal diseases are that (1) they are a major cause of mortality in the young and elderly, (2) current vaccines have limited efficacy and coverage, (3) vaccination is not always accessible and (4) pneumococcal disease presents an ecoomic burden. ImmBio is developing next-generation vaccines against serious infectious disease targets, starting with a vaccine against pneumococcal disease, utilising its proprietary technology platforms to directly induce immunity via dendritic cells.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

During the Feasibility Study, ImmBio has completed a full analysis of the technical and business potential of its new vaccine. During the project the company has expanded its knowledge primarily with regards to the required clinical validation and regulatory approval for European market launch.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

PnuBioVax™ (PBV) is a next-generation, multi-antigen, serotype-independent and adjuvant-free prophylactic vaccine against invasive pneumococcal disease. Although most competing vaccines are effective against the variants they specifically target, there are significant issues associated with them; i) high production costs, ii) low breadth of protection, iii) promotion of antibiotic resistance and, iv) their efficacy depends on the prevalence of the targeted variants in the different geographical regions. Immbio intends to bring to market a clinically validated vaccine against pneumococcal disease that will increase prevention and be more widely accessible thanks to its lower cost of production.

ImmBio